FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2040765493> ?p ?o ?g. }

• W2040765493 endingPage "889" @default.
• W2040765493 startingPage "881" @default.
• W2040765493 abstract "The purpose of this report is to review immunotherapies under investigation for patients with renal cell carcinoma (RCC), the most common form of kidney cancer, for which the incidence and mortality rate continue to increase.To summarize and evaluate current data on immunotherapies for RCC and discuss issues to be resolved before integration into the RCC treatment paradigm.A search of Medline, clinicaltrials.gov, and congress abstracts/treatment guidelines was performed in May 2012 using the following terms (and variations): metastatic renal cell carcinoma, practice guidelines, response/resistance to current treatments, immunotherapy, novel immunotherapeutic strategies, T-cell modulation, immune priming, innate immunity, and combination therapy.Prior to the advent of novel agents targeting the vascular endothelial growth factor and mechanistic target of rapamycin pathways, interleukin-2 (IL-2) and interferon-α were the mainstays of RCC treatment. IL-2 remains one of the only treatments capable of curing advanced RCC, albeit in few patients. Despite recent advances, unmet need still exists for patients in the adjuvant setting, those with poor prognostic factors, and those who have progressed on prior targeted therapies. Improved understanding of host-tumor immune interactions has led to development of novel immunotherapeutic agents, including antibodies against immune checkpoint proteins (eg, programmed death-1 and cytotoxic T-lymphocyte antigen-4), and various vaccines. Because many of these compounds are in development, clinical experience with them is limited, although some have demonstrated activity in preliminary studies.It is not yet clear where these new immunotherapies will fit into RCC treatment paradigms, but they may provide new options for patients whose current choices are limited. Furthermore, predictive biomarkers are needed to identify patients who will derive the greatest benefit from immunotherapy." @default.
• W2040765493 created "2016-06-24" @default.
• W2040765493 creator A5000997350 @default.
• W2040765493 creator A5020223699 @default.
• W2040765493 creator A5050166344 @default.
• W2040765493 date "2013-05-01" @default.
• W2040765493 modified "2023-10-16" @default.
• W2040765493 title "Novel Immunotherapeutic Strategies in Development for Renal Cell Carcinoma" @default.
• W2040765493 cites W1572411832 @default.
• W2040765493 cites W1968964239 @default.
• W2040765493 cites W1984545852 @default.
• W2040765493 cites W1986137152 @default.
• W2040765493 cites W1987232964 @default.
• W2040765493 cites W1992350807 @default.
• W2040765493 cites W1993564928 @default.
• W2040765493 cites W2011188477 @default.
• W2040765493 cites W2016536591 @default.
• W2040765493 cites W2036240115 @default.
• W2040765493 cites W2044601661 @default.
• W2040765493 cites W2045155966 @default.
• W2040765493 cites W2048376332 @default.
• W2040765493 cites W2048800818 @default.
• W2040765493 cites W2050302729 @default.
• W2040765493 cites W2058805068 @default.
• W2040765493 cites W2076537509 @default.
• W2040765493 cites W2093770542 @default.
• W2040765493 cites W2097062765 @default.
• W2040765493 cites W2097995306 @default.
• W2040765493 cites W2099088585 @default.
• W2040765493 cites W2100086637 @default.
• W2040765493 cites W2101653483 @default.
• W2040765493 cites W2102575291 @default.
• W2040765493 cites W2103959341 @default.
• W2040765493 cites W2117547860 @default.
• W2040765493 cites W2121207632 @default.
• W2040765493 cites W2123914905 @default.
• W2040765493 cites W2127725920 @default.
• W2040765493 cites W2130826590 @default.
• W2040765493 cites W2135139265 @default.
• W2040765493 cites W2143381422 @default.
• W2040765493 cites W2143813821 @default.
• W2040765493 cites W2149456801 @default.
• W2040765493 cites W2151906398 @default.
• W2040765493 cites W2155312231 @default.
• W2040765493 cites W2160834915 @default.
• W2040765493 cites W2162424705 @default.
• W2040765493 cites W2171469612 @default.
• W2040765493 cites W2242950936 @default.
• W2040765493 cites W2911611736 @default.
• W2040765493 cites W4234636179 @default.
• W2040765493 doi "https://doi.org/10.1016/j.eururo.2012.10.006" @default.
• W2040765493 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23084331" @default.
• W2040765493 hasPublicationYear "2013" @default.
• W2040765493 type Work @default.
• W2040765493 sameAs 2040765493 @default.
• W2040765493 citedByCount "39" @default.
• W2040765493 countsByYear W20407654932013 @default.
• W2040765493 countsByYear W20407654932014 @default.
• W2040765493 countsByYear W20407654932015 @default.
• W2040765493 countsByYear W20407654932016 @default.
• W2040765493 countsByYear W20407654932017 @default.
• W2040765493 countsByYear W20407654932018 @default.
• W2040765493 countsByYear W20407654932019 @default.
• W2040765493 countsByYear W20407654932020 @default.
• W2040765493 countsByYear W20407654932021 @default.
• W2040765493 countsByYear W20407654932022 @default.
• W2040765493 countsByYear W20407654932023 @default.
• W2040765493 crossrefType "journal-article" @default.
• W2040765493 hasAuthorship W2040765493A5000997350 @default.
• W2040765493 hasAuthorship W2040765493A5020223699 @default.
• W2040765493 hasAuthorship W2040765493A5050166344 @default.
• W2040765493 hasConcept C126322002 @default.
• W2040765493 hasConcept C143998085 @default.
• W2040765493 hasConcept C203014093 @default.
• W2040765493 hasConcept C2777472916 @default.
• W2040765493 hasConcept C2777701055 @default.
• W2040765493 hasConcept C2777863537 @default.
• W2040765493 hasConcept C2781068499 @default.
• W2040765493 hasConcept C71924100 @default.
• W2040765493 hasConcept C8891405 @default.
• W2040765493 hasConceptScore W2040765493C126322002 @default.
• W2040765493 hasConceptScore W2040765493C143998085 @default.
• W2040765493 hasConceptScore W2040765493C203014093 @default.
• W2040765493 hasConceptScore W2040765493C2777472916 @default.
• W2040765493 hasConceptScore W2040765493C2777701055 @default.
• W2040765493 hasConceptScore W2040765493C2777863537 @default.
• W2040765493 hasConceptScore W2040765493C2781068499 @default.
• W2040765493 hasConceptScore W2040765493C71924100 @default.
• W2040765493 hasConceptScore W2040765493C8891405 @default.
• W2040765493 hasIssue "5" @default.
• W2040765493 hasLocation W20407654931 @default.
• W2040765493 hasLocation W20407654932 @default.
• W2040765493 hasOpenAccess W2040765493 @default.
• W2040765493 hasPrimaryLocation W20407654931 @default.
• W2040765493 hasRelatedWork W128229229 @default.
• W2040765493 hasRelatedWork W1996150995 @default.
• W2040765493 hasRelatedWork W2002891289 @default.
• W2040765493 hasRelatedWork W2090324576 @default.

• next